ESR1 and breast carcinoma: In the dose escalation, phase 1 portion of a first-in-human phase 1/2 study (NCT04072952), vepdegestrant demonstrated antitumor activity and was well tolerated in heavily pretreated patients with ER+/HER2- advanced breast cancer at all doses tested (30 to 700 mg per day) [23].